Results of Operations and Financial Condition. On July 30, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Director — Daniel M. Skovronsky M.D., Ph.D.: Dr. Skovronsky resigned as a director without any disagreement or issues with the company.

The filing primarily concerns stockholder approvals for equity incentive plans and amendments to existing plans.

Results of Operations and Financial Condition. On May 5, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended March 31, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Results of Operations and Financial Condition. On February 23, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includ…

Results of Operations and Financial Condition. On January 12, 2026, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue for the quarter and full year ended December 31, 2025. The Company also introduced full year 2026 financial guidance. In addition, the Company is announcing certain preliminary volume information for the full year ended December 31, 2025. Specifically, the Company expects total test volumes in 2025 of approximately 1.5 million, a 1…

Results of Operations and Financial Condition. On November 3, 2025, Myriad Genetics, Inc. (“Myriad”) furnished a Current Report on Form 8-K that included a press release reporting financial results for the three months ended September 30, 2025 (the "Original Form 8-K"). Myriad is filing this Amendment No. 1 on Form 8-K/A to amend the Original Form 8-K solely to correct the amount shown for Cash, cash equivalents, and restricted cash at beginning of the period for the three months ended Septem…

Results of Operations and Financial Condition. On November 3, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includin…

Chief Financial Officer — Scott J. Leffler: Mr. Leffler departed as Chief Financial Officer with a severance package.

Principal Accounting Officer — Natalie Munk: Natalie Munk resigned as Principal Accounting Officer, and Benjamin R. Wheeler was appointed to the role.

Chief Financial Officer — Scott J. Leffler: Scott J. Leffler departed as Chief Financial Officer, and Ben R. Wheeler was internally promoted to the role.

Results of Operations and Financial Condition. On August 5, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement. On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum p…

Other Events. On July 31, 2025, the Company issued a press release announcing the entry into the Credit Agreement which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The filing is about amendments to the equity incentive plan and does not involve any management changes.

Results of Operations and Financial Condition. On May 6, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended March 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report o…

President, Chief Executive Officer and Director — Paul J. Diaz: Paul J. Diaz is stepping down to join a private equity firm but will continue as a consultant.

Results of Operations and Financial Condition. On February 24, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended December 31, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Results of Operations and Financial Condition. On January 15, 2025, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue, loss per share and adjusted earnings per share results for the quarter and full year ended December 31, 2024 and cash and cash equivalents as of December 31, 2024. The Company also introduced full year 2025 financial guidance. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by referen…

Director — Mark S. Davis: The Board of Directors appointed Mark S. Davis as a new Director and increased the size of the Board from eight to nine members.

Regulation FD Disclosure. As previously disclosed, beginning on August 9, 2021, two purported shareholder derivative complaints were filed with the Court of Chancery of the State of Delaware (the “ Court ”) against Myriad Genetics, Inc. (the “ Company ”), as nominal defendant, and certain of the Company’s current and/or former directors and officers. On March 3, 2022, the cases were consolidated under the caption In re Myriad Genetics, Inc. Stockholder Derivative Litigation , Case No. 2021-06…

Results of Operations and Financial Condition. On November 7, 2024, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months September 30, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K and Exhibit 99.1 contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform A…

Results of Operations and Financial Condition. Myriad Genetics, Inc. (the “Company”) previously announced by press release that it will hold an Investor Event on October 9, 2024 — in person at the Westin Grand Central Hotel in New York City and via a simultaneous live webcast. In connection with the Investor Event, the Company is disclosing certain preliminary financial data for the third quarter of 2024, specifically that the Company expects third quarter 2024 revenue of between approximatel…

Results of Operations and Financial Condition. On August 6, 2024, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended June 30, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K and Exhibit 99.1 contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Ac…